• 1. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 2. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 5. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996

Research Brief on 3-bromo-7-chloro-Thieno[3,2-b]pyridine (CAS: 1334645-51-0): Recent Advances and Applications in Chemical Biology and Medicine

The compound 3-bromo-7-chloro-Thieno[3,2-b]pyridine (CAS: 1334645-51-0) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This heterocyclic scaffold serves as a versatile building block for the synthesis of novel bioactive molecules, particularly in the development of kinase inhibitors and other targeted therapies. Recent studies have explored its role in modulating key signaling pathways implicated in cancer, inflammation, and neurodegenerative diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 3-bromo-7-chloro-Thieno[3,2-b]pyridine derivatives as potent inhibitors of cyclin-dependent kinases (CDKs), with compound 7a showing IC50 values below 10 nM against CDK2 and CDK4. The researchers employed structure-activity relationship (SAR) studies to optimize the substitution pattern, revealing that the bromo and chloro substituents at positions 3 and 7, respectively, are critical for maintaining high binding affinity to the ATP-binding pocket of CDKs.

In addition to its kinase inhibitory properties, recent investigations have highlighted the compound's potential in PET radiopharmaceutical development. A team at MIT reported the successful incorporation of 3-bromo-7-chloro-Thieno[3,2-b]pyridine into a novel tracer for imaging tau protein aggregates in Alzheimer's disease. The bromine atom at position 3 allowed for straightforward radiohalogenation with fluorine-18, while the chloro substituent at position 7 contributed to improved blood-brain barrier penetration.

The synthetic accessibility of 3-bromo-7-chloro-Thieno[3,2-b]pyridine has also been a focus of recent research. A 2024 Nature Protocols paper detailed an improved two-step synthesis starting from commercially available 3-aminothiophene, achieving an overall yield of 68% with excellent purity (>99%). This methodological advancement has facilitated broader exploration of the compound's medicinal chemistry potential by reducing production costs and time.

Emerging safety and ADME (Absorption, Distribution, Metabolism, and Excretion) data suggest that 3-bromo-7-chloro-Thieno[3,2-b]pyridine-based compounds generally exhibit favorable pharmacokinetic profiles. A recent preclinical study demonstrated good oral bioavailability (F = 52-68% in rodent models) and moderate plasma protein binding (75-82%), making this scaffold particularly attractive for drug discovery programs targeting central nervous system disorders.

Looking forward, several pharmaceutical companies have included 3-bromo-7-chloro-Thieno[3,2-b]pyridine derivatives in their pipelines, with two candidates currently in Phase I clinical trials for oncology indications. The versatility of this scaffold continues to inspire new research directions, including its potential application in PROTAC (proteolysis targeting chimera) development and as a warhead in covalent inhibitor design.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)